Category Medicine and Healthcare
Press Release
Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly
Robotic smelltech by AI Nose moves from concept to integration in weeks Partnership fast-tracks robotic smell integration as global service robotics market nears $40.6B, Japan $1.2B Read More
Press Release
A Place to Heal: Virtue Recovery Center Stands With Veterans and Families Across the United States
Virtue Recovery Center Offers Veterans a Place to Heal and Be Heard Virtue Recovery Center in Las Vegas offers veterans compassionate, personalized care for PTSD, addiction, and mental health recovery. Read More
Press Release
Interactive Strength Inc. (Nasdaq:TRNR) Secures Record $1M+, 480-Unit Wattbike Order from US Distributor, WOODWAY
Record order for Wattbike builds on brand momentum and the launch of the Air Pro, the next generation of the best-selling elite performance training bike used globally by professional sports teams Geographic expansion, especially in the US, is key to the strategy of TRNR acquiring the UK-based Wattbike Wattbikes are installed in more than 3,000 Gyms in the UK but only a few hundred in the US - providing a significant opportunity for US growth Read More
Press Release
CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus
With the global CBD market expected to exceed $60 billion by 2030, and the mental wellness industry surging past $500 billion, CBD Life Sciences Inc. (OTC: CBDL) is strategically positioning itself at the center of two of the fastest-growing markets in modern health. Read More
Press Release
DEA Officials Face Potential Dismissal Under Trump's Schedule F Workforce Reform Plan
"For too long, these DEA officials, Thomas Prevoznik, Matthew Strait and Aarathi Haig have operated with impunity while denying patients access to critical medicines," said Duane Boise, CEO of MMJ BioPharma Cultivation. Read More
Press Release
DEA MARIJUANA SCAM: As DEA Cannabis Program Implodes This 4/20, MMJ Stands Alone in Pursuit of Real Medicine
MMJ's DEA lawsuit continues moving through the federal courts. The 8 organizations who have been issued DEA federal cannabis registrations since 2021, all are incapable of growing pharmaceutical-grade marijuana and 7 are now either inactive or bankrupt. Read More
Press Release
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's PRIME program for novel medicines targeting unmet medical needs and the FDA's Breakthrough Therapies program Read More
Press Release
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract accepted by MASCC shows additional significant results for breast cancer subgroup Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting Read More
Press Release
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments - - XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne - Read More
Press Release
